Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

Executive Summary

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Advertisement

Related Content

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
Confo Therapeutics Raises €30m Series A To Drug Difficult Targets
Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Freshly Funded Symic Bio Plays In The Matrix
Venture Funding Deals
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection
Bayer And CRISPR Form Cutting Edge Gene Editing JV

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125182

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel